Swiss Medical Device Maker Ypsomed To Sell Diabetes Business

(MENAFN- Swissinfo) Bern-based injection device manufacturer Ypsomed announced on Tuesday that it was selling its diabetes-related activities to another Swiss company TecMed. The transaction is worth CHF420 million ($517 million). This content was published on April 22, 2025 - 14:26 1 minute Keystone-SDA

• Français fr Ypsomed cède les activités liées au diabète à TecMed Original Read more: Ypsomed cède les activités liées au diabète à TecMe

+ Get the most important news from Switzerland in your inbox

“Proceeds from the sale will finance the expansion of the injection systems business,” said a statement. The transaction is expected to be completed in the second half of the year, subject to regulatory approval of the ongoing demerger.

In November, the company announced the start of the process of selling its diabetes care business. Following a comprehensive marketing phase involving both strategic and financial buyers, TecMed“emerged as the ideal partner to take over YpsomedExternal link 's diabetes care business”.

Translated from German by DeepL/jdp

How we work

We select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate them into English. An editor then briefly reviews the translation for clarity and accuracy before publication. Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.

Did you find this explanation helpful? Please fill out this short survey to help us understand your needs by clicking hereExternal link .

External Content Popular Stories More Workplace Switzerland Trump tariff shock: how Switzerland is positioning itself Read more: Trump tariff shock: how Switzerland is positioning itsel

MENAFN22042025000210011054ID1109459391